**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript NO: 13158**

**Columns: ORIGINAL ARTICLE**

***Case Control Study***

**Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma**

Song DS *et al*. Multimodal treatment for large HCC

Do Seon Song, Soon Woo Nam, Si Hyun Bae, Jin Dong Kim, Jeong Won Jang, Myeong Jun Song, Sung Won Lee, Hee Yeon Kim, Young Joon Lee, Ho Jong Chun, Young Kyoung You, Jong Young Choi, Seung Kew Yoon

**Do Seon Song, Soon Woo Nam, Si Hyun Bae, Jeong Won Jang, Myeong Jun Song, Sung Won Lee, Hee Yeon Kim, Jong Young Choi, Seung Kew Yoon**, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 137-040, South Korea

**Jin Dong Kim,** Department of Internal Medicine, Cheju Halla General Hospital, Jeju690-766, South Korea

**Young Joon Lee, Ho Jong Chun**, Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul 137-040, South Korea

**Young Kyoung You**, Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul 137-040, South Korea

**Author contributions:** Bae SH and Kim JD designed the research; Jang JW, Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, You YK, Choi JY, and Yoon SK performed the research; Song DS and Kim JD analyzed the data; Song DS and Nam SW wrote the paper.

**Supported by** National R and D Program grant for cancer control from the Ministry of Health, Welfare and Family Affairs, South Korea, No. R0620390-1

**Correspondence to: Soon Woo Nam, MD, PhD, Associate Professor,** Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-701, South Korea*.* drswnam@hanmail.net

**Telephone:** +82-2-22582073 **Fax:** +82-2-34814025

**Received:** August 8, 2014 **Revised:** October 3, 2014

**Accepted:** November 18, 2014

**Published online:**

**Abstract**

**Aim:** To investigate the efficacy and safety of transarterial chemoembolization (TACE)–based multimodal treatment in patients with large hepatocellular carcinoma (HCC).

**Methods:** A total of 146 consecutive patients were included in the analysis, and their medical records and radiological data were reviewed retrospectively.

**Results:** In total, 119 patients received TACE-based multi-modal treatments, and the remaining 27 received conservative management. Overall survival (*P <* 0.001) and objective tumor response (*P =* 0.003) were significantly better in the treatment group than in the conservative group. After subgroup analysis, survival benefits were observed not only in the multi-modal treatment group compared with the TACE-only group (*P =* 0.002) but also in the surgical treatment group compared with the loco-regional treatment-only group (*P <* 0.001). Multivariate analysis identified tumor stage (*P <* 0.001) and tumor type (*P =* 0.009) as two independent pre-treatment factors for survival. After adjusting for significant pre-treatment prognostic factors, objective response (*P* < 0.001), surgical treatment (*P* = 0.009), and multi-modal treatment (*P* = 0.002) were identified as independent post-treatment prognostic factors.

**Conclusion:** TACE-based multi-modal treatments were safe and more beneficial than conservative management. Salvage surgery after successful downstaging resulted in long-term survival in patients with large, unresectable HCC.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Hepatocellular carcinoma; Multimodal treatment; Transarterial chemoembolization; Salvage surgery

**Core tip:** The aim of this study was to investigate the efficacy of transarterial chemoembolization (TACE)–based multimodal treatment in patients with large hepatocellular carcinoma (HCC). The primary findings of this study were as follows: (1) The overall survival was significantly longer in the treatment group than in the conservative group; (2) Survival benefits were observed not only in the surgical treatment group (TACE + resection or transplantation) compared with the localized treatment group (TACE + ablation or radiotherapy) but also in the combination treatment group compared with the TACE-only group; and (3) objective response, surgical treatment, and multi-modality were independent factors for survival.

Song DS, Nam SW, Bae SH, Kim JD, Jang JW, Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, You YK, Choi JY, Yoon SK. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the sixth most-common cancer worldwide and the third most-common cause of cancer mortality[[1](#_ENREF_1)]. In clinical practice, the majority of HCC patients are diagnosed at an inoperable stage, and prognosis is assumed to be poor. The recent guidelines issued by the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) endorse the Barcelona Clinic Liver Cancer (BCLC) staging system[[2](#_ENREF_2),[3](#_ENREF_3)]. BCLC guidelines have the advantage of combining performance status, liver function, and tumor extent to classify patients into early (A), intermediate (B), advanced (C), and terminal (D) stages, and it links staging with treatment modalities and with an estimation of life expectancy. This guideline recommends transarterial chemoembolization (TACE) in BCLC-B and sorafenib in BCLC-C as standard treatments. Although BCLC guidelines have been extensively validated, a heterogeneous population of patients with intermediate-stage HCC or with advanced-stage HCC has consistently raised issues in clinical practice. Because multiple variables affect the clinical course of HCC, no single treatment strategy can be applied to all patients. Therefore, therapy should be tailored to each patient’s individual needs using a multidisciplinary approach, particularly in cases of unresectable, large HCC.

The most widely used loco-regional therapies for the treatment of intermediate stage HCC involve TACE. In early 2000, two randomized controlled trials (RCTs) and systematic reviews reported that TACE improves the survival of patients with unresectable HCC compared with those who receive supportive treatment[[4-7](#_ENREF_4)]. Although TACE is typically contraindicated in advanced HCC patients with portal vein (PV) invasion because of the potential risk of hepatic insufficiency, it has been suggested that TACE can be safely performed, even in those patients with PV invasion[[8](#_ENREF_8)]. Therefore, it has also been used in patients with advanced HCC with PV invasion as a palliative treatment, and several studies have reported that it confers a survival benefit to these advanced patients[[9-11](#_ENREF_9)]. However, limited studies have evaluated the proper treatment and the efficacy of TACE in cases of large HCCs (> 10 cm) with or without vascular invasion, which are frequently observed in clinical practice. The aim of this study was to evaluate the efficacy and safety of TACE–based multimodal treatment in patients with unresectable, large HCC.

**MATERIALS AND METHODS**

***Patients***

This was a retrospective case-control study aimed at evaluating the therapeutic efficacy of combination therapy with TACE and other treatment modalities for large HCC in comparison with that of optimal supportive treatment. The HCC database at our center was retrospectively reviewed between June 1995 and December 2007. The inclusion criteria for eligibility in this study were as follows: (1) treatment-naïve adult patients who were newly diagnosed with HCC at our center; (2) HCC of over 10 cm in size; (3) Eastern Cooperative Oncology Group performance status of 0-2; and (4) Child-Turcotte-Pugh functional class of A (score of 5 or 6). Patients with distant extrahepatic metastasis and severe comorbidity and those who were transferred to another center without receiving treatment were excluded. This study was approved by the local ethics committee.

The diagnosis of HCC was made either pathologically or based upon elevated serum alpha-fetoprotein levels (> 200 ng/mL) with typical radiological findings (arterial hypervascularity and venous/late-phase washout). All patients were staged according to the modified Union for International Cancer Control staging system[[12](#_ENREF_12)]. The gross type of HCC was defined based on the extent of demarcation, as described in a previous study[[10](#_ENREF_10)].

***Therapeutic modalities including TACE***

Almost all therapeutic approaches were selected by the HCC tumor board team, which consisted of hepatologists, surgeons, interventional radiologists, a medical oncologist and radiation oncologists. All patients in the treatment group underwent a transarterial infusion of epirubicin (50 mg/m2) and cisplatin (60 mg/m2) in a mixture of 5–10 mL Lipiodol® (Guerbet, Aulnay-Sous-Bois, France) *via* femoral approach, which was accompanied by embolization using gelfoam in selected cases. The patients received an additional systemic infusion of 5-fluorouracil (5-FU) (200 mg/m2) for 12 h after completing the transarterial procedure[[10](#_ENREF_10)]. Unless there was a contraindication, the TACE sessions were repeated every 4-6 wk, and other additional therapies were performed as necessary for the downstaging of the tumor. Additional therapeutic modalities included radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), radiation therapy and systemic chemotherapy with the ECF regimen (epirubicin + cisplatin + 5-FU). Surgical resection or transplantation was considered for those patients who were downstaged following local therapy. Before surgical resection or transplantation, chest computed tomography (CT) and positron emission tomography (PET) CT scans were performed to exclude the presence of extra-hepatic metastasis. Liver transplantations were performed in the patients who met the University of California, San Francisco (UCSF) criteria (Figure 1).

All patients who met the inclusion criteria were recommended to receive the treatment that had been determined by the tumor board. The patients who refused HCC treatment against medical advice, with the exception of those receiving symptomatic support, were classified as the conservative care group. Sorafenib could not be administered to the treatment group and conservative group because it was not available during the study period.

***Assessment of treatment response and adverse effects***

Treatment response was assessed after every TACE session using dynamic enhanced CT or magnetic resonance imaging (MRI), and the best response during serial TACE was taken as the overall response. Tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (RECIST)[[13](#_ENREF_13)]. A complete response (CR) was defined as the disappearance of any intra-tumoral arterial enhancement, a partial response (PR) was defined as a ≥ 30% decrease in the sum of the diameters of viable lesions, progressive disease (PD) was defined as a ≥ 20% increase in the sum of the diameters of viable lesions, and stable disease (SD) was defined as any case that did not qualify as either PR or PD.

The primary endpoint of this study was overall survival (OS), and the secondary endpoint was objective response (OR). OS was defined as the time from the first session of TACE to death, and OR was defined as the sum of the complete response and partial response. The treatment-related adverse events were assessed for 1–2 wk after each treatment using the National Cancer Institute Common Toxicity Criteria v3.0, and grade 3 or 4 toxicities were noted.

***Statistical analysis***

Statistical analyses were performed using the Statistical Package for Social Science software (SPSS 14.0 for Windows; SPSS, Inc., Chicago, IL). The results are presented as the number (%) or median (range), as appropriate. The Mann-Whitney test and Fisher’s exact test or the **2 test were used for comparisons between the treatment group and the conservative group. Categorical variables were evaluated using Fisher’s exact test or the chi-square test. Cumulative survival rates were estimated using the Kaplan–Meier method, and differences were analyzed using the log-rank test. To identify the independent factors for survival among pre-treatment variables and treatment-related variables, we used Cox proportional hazard regression models with backward elimination. In the multivariate analysis using treatment-related variables, hazard ratios were adjusted for significant variables in the multivariate analysis of pre-treatment variables due to the possibility of multi-collinearity. The variables that showed significant or marginal association (*P* < 0.1) by univariate analysis were subsequently included in multivariate analysis. A *P* value of less than 0.05 was considered statistically significant.

**RESULTS**

***Patient characteristics***

Using the aforementioned selection criteria, a total of 146 consecutive patients were enrolled in this study. The baseline characteristics of the patients are summarized in Table 1. A total of 119 patients (81.5%) were treated with the TACE-based multimodal procedure, and 27 (18.5%) received supportive treatment. One hundred and thirty patients (89.0%) were male, and the median age of the 146 patients was 52 years (range, 30-79 years). The etiology of the underlying liver disease was hepatitis B virus in 115 (78.8%), hepatitis C virus in 7 (4.8%), and alcoholism in 8 patients (5.5%). One hundred and eight patients (74.0%) had evidence of PV thrombosis (PVT) at baseline. There was no significant difference between the two groups in terms of the etiology of underlying disease, serum alpha-fetoprotein (AFP) level, maximal tumor size, tumor type, proportion of PVT, and stage. The median age of patients in the treatment group was lower than that of patients in the conservative group (*P =* 0.014), and male patients were more common in the treatment group (*P =* 0.002).

***Treatment response***

In the treatment group, a total of 513 TACE sessions were performed with a median of 3 sessions per patient (range: 1–17). In total, 71 (59.7%) out of 119 patients received combination therapy. As for treatment modality, a median of 2 methods (range: 1-5) was administered. Systemic chemotherapy was administered in 46 patients, radiotherapy in 25, ablation therapy, such as RFA or PEI, in 21, surgical resection in 13, and liver transplantation in 4 patients.

Tumor responses were assessable in 122 of 146 patients (83.6%), while 24 (16.4%) were not assessable due to poor patient condition or loss to follow-up. The intent-to-treat analysis revealed that 14 of 102 patients (13.7%) experienced complete remission (CR), 15 (14.7%) experienced partial remission (PR), 31 (30.4%) experienced stable disease (SD), and 42 (41.2%) developed progressive disease (PD) in the treatment group. Therefore, the objective response rate was 28.4%, and 60 patients (58.8%) achieved successful disease control (CR + PR + SD) in the treatment group. In the conservative group, SD and PD were observed in 3 (15.0%) and 17 patients (85.0%), respectively, and there was no CR and PR. The objective response rate of the treatment group was significantly higher than that of the conservative group (28.4% *vs* 0.0%, *P =* 0.003). The disease control rate was also better in the treatment group than in the conservative group (58.8% *vs* 15.0%, *P <* 0.001) (Table 2).

***Survival and prognostic factors***

The median follow-up period was 8.5 months (range: 0.8-129.4 mo), and the median overall survival (OS) in this study was 8.7 mo (95%CI: 7.0-10.4 mo). OS was significantly longer in the treatment group than in the conservative group (median of 10.3 *vs* 4.0 mo, *P <* 0.001) (Figure 2A). Following subgroup analysis, survival benefits were observed not only in the surgical treatment group (TACE + resection or transplantation) compared with the localized treatment group (TACE + RFA, PEI or radiotherapy) (median of 31.6 *vs* 9.1 mo, *P* < 0.001) (Figure 2B) but also in the combination treatment group (TACE + other modalities) compared with the TACE-only group (median of 12.8 *vs* 8.1 mo, *P =* 0.002) (Figure 2C). The estimated survival rates at 6, 12, 18, and 24 mo were 72.0%, 43.0%, 28.2%, and 23.5%, respectively, for the treatment group, whereas the estimated 6- and 12-mo survival rates were 18.5% and 3.7% for the conservative group (Table 3).

Univariate analysis revealed the following 4 potential prognostic factors related to survival among the baseline characteristics in the treatment group: age (*P =* 0.062), tumor type (*P <* 0.001), portal vein thrombosis (*P <* 0.001), and tumor stage (*P <* 0.001). Upon multivariate analysis, tumor type ( HR = 1.849; 95%CI: 1.165–2.934, *P =* 0.009) and stage (HR = 2.828; 95%CI: 1.740-4.595, *P <* 0.001) were identified as independent factors for survival (Table 4). Multivariate analysis for identifying the influences of treatment response and treatment modality revealed that objective response (HR = 2.870; 95%CI: 1.678 - 4.910, *P* < 0.001), surgical treatment (HR = 2.301; 95%CI: 1.227-4.317, *P =* 0.009), and multi-modality (HR = 1.835; 95%CI: 1.242–2.714, *P =* 0.002) were also independent factors for survival (Table 5).

***Subgroup analysis of baseline characteristics in the treatment group***

Because the surgical treatment significantly influenced patient survival, we compared the baseline characteristics between the surgical treatment group and non-surgical treatment group (Table 6). There were no statistically significant differences between two groups. However, the surgical treatment group tended to have more favorable prognostic factors, such as well-demarcated tumors, no PVT, and lower tumor stage (*P* = 0.051, *P* = 0.094, and *P* = 0.071, respectively).

***Treatment-related toxicity***

Grade 3 and grade 4 treatment-related toxicities were investigated in the treatment group. The most common G3-4 toxicities were serum transaminase elevation (45.4%) and gastrointestinal toxicity, such as nausea, vomiting and anorexia (29.4%), jaundice (26.9%), neutropenia (23.5%), thrombocytopenia (16.0%), and anemia (14.3%). However, the toxicities were transient and successfully managed using conservative treatment. In addition, there were no significant life-threatening adverse effects related to the treatment.

**DISCUSSION**

Although the surveillance program for high-risk patients has improved the early detection of HCC and decreased tumor-related mortality[[14](#_ENREF_14)], a substantial proportion of patients present with a large HCC (≥ 10 cm diameter)[[6](#_ENREF_6)]. The prognosis of large HCC is very poor because tumor size is a significant risk factor for vascular invasion and intra- and extra-hepatic spreading[[15-17](#_ENREF_15)]. In patients with large HCC, surgical resection or TACE are the generally accepted treatment options. The BCLC guidelines recommend sorafenib for the treatment of advanced HCC patients with PVT. However, despite recent advances in treatment, it is unclear which option is the optimal treatment modality for these patients. In this study, we showed that TACE-based treatments confer survival benefits to patients with large HCC (*P <* 0.001). Moreover, combination therapy with TACE and an additional treatment was associated with a better outcome than that of TACE alone, especially in cases of curative resection or liver transplantation (*P <* 0.001).

The BCLC staging system includes multiple variables affecting the course of HCC and treatment response, including liver function, performance status, cancer-related symptoms and tumor stage[[2](#_ENREF_2),[3](#_ENREF_3)]. In addition, it assigns each stage with a survival rate and a treatment algorithm. However, this staging system not only fails to suggest an appropriate combination treatment strategy but also does not provide suggestions on salvage therapy, because it only recommends a single treatment option as the first line of therapy at each stage. Because of the heterogeneity in presentation and diversity of patient responses to therapy, no single treatment strategy can be applied to all patients, and multimodal treatment is required to manage HCC patients in clinical practice. Many studies supporting a multimodal treatment approach for HCC have been performed, particularly with TACE. The combination therapy with TACE and percutaneous ablation, such as PEI or RFA, has been shown to be superior to TACE alone or percutaneous ablation therapy alone[[18-20](#_ENREF_18)]. Some studies have also shown that combination therapy with TACE and radiotherapy improves patient survival, compared with TACE alone[[21](#_ENREF_21),[22](#_ENREF_22)]. Recently, substantial numbers of clinical trials assessing the efficacy of sorafenib in combination with TACE have been completed or are currently underway[[23-25](#_ENREF_23)]. However, it is still unclear whether multimodal treatments provide better outcomes in patients with large HCC because few studies have been performed on this group, and no randomized controlled studies have been conducted. In this study, we showed that TACE-based therapy improved patient survival compared with supportive care in patients with large HCC (*P <* 0.001), and combination therapy with TACE and an additional treatment modality prolonged overall survival compared with that of TACE alone (*P <* 0.001) (Figure 3). In addition, multi-modal treatment was identified as a significant prognostic factor by multivariate analysis (*P* = 0.002) (Table 5). Although TACE procedure has the risk of severe complications, such as hepatic arterial occlusion, liver abscess, and spontaneous rupture of tumor[[26](#_ENREF_26)], there were no serious complications observed in this study. These results suggest that TACE-based treatment may be safe and effective and that multimodal treatment is associated with better prognosis in patients with large HCC and preserved liver function.

Surgical resection is the mainstay of treatment for resectable tumors. Recently, Yang *et al*[[27](#_ENREF_27)] reported that surgical resection is associated with better outcomes than TACE in patients with large HCC (≥ 10 cm). However, a substantial proportion of large HCC are unresectable because of intrahepatic or extrahepatic metastasis or the risk of post-operative hepatic dysfunction. The treatment of these unresectable HCCs is mainly palliative, aiming to relieve symptoms, and if possible, prolong survival. With improvements in regional and systemic therapies, some treatments that originally aim at palliation can downstage tumors from unresectable to resectable. Although the downstaging of HCC prior to hepatic resection has not been widely investigated, some previous studies have shown that successful downstaging can improve patient prognosis[[28-30](#_ENREF_28)]. The tumor downstaging strategy has been studied more frequently in association with liver transplantation than resection. The use of successful downstaging therapy in patients with HCC exceeding the accepted transplant criteria has revealed excellent post-transplant results[[31-33](#_ENREF_31)]. In addition, patients who received surgical treatment after downstaging using TACE had significantly longer survival than those who received TACE with loco-regional treatment in this study (*P <* 0.001), and surgical treatment was an independent prognostic factor for survival (*P* = 0.009). These results suggest that salvage surgery after successful downstaging leads to better outcomes in patients with large, unresectable HCC. Therefore, clinicians should attempt downstaging in these cases using aggressive treatment and a multimodal strategy and consider surgical treatment, such as resection or transplant, as an option if downstaging is successful.

As HCC treatments have been developed, novel transarterial approaches, such as TACE with drug-eluting beads (DEB) or transarterial radioembolization (TARE), have been introduced. Recent studies have reported that the use of TACE with DEB leads to better outcomes compared with conventional TACE in the treatment of patients with advanced HCC[[34](#_ENREF_34),[35](#_ENREF_35)]. In addition, TARE appears to be safe in the treatment of more advanced disease, including portal vein invasion and large HCC[[36](#_ENREF_36),[37](#_ENREF_37)]. These modalities were not included as a treatment option in this study. However, considering the advantages of these transarterial treatments, multimodal strategies using these approaches are also expected to provide benefits to patients with unresectable HCC, and further prospective studies are necessary.

This study had some limitations. First, a retrospective design was used, which could have led to selection bias. However, we consecutively enrolled patients during the study period, and there were no significant differences between the treatment group and conservative group. Second, the combination therapies used in the TACE-based treatment group included heterogeneous modalities, such as systemic chemotherapy, RFA, PEI, and radiation therapy. Moreover, some patients who achieved successful downstaging received surgical resection or transplantation. Although these additional treatments used in combination with TACE resulted in better outcomes, this study may have been inherently biased due to the heterogeneous treatments. Thus, prospective studies are necessary to resolve this issue. Third, patients who were treated with sorafenib, which is a molecular-targeted agent, were not included in this study. We included a substantial number of patients with advanced HCC (BCLC stage C). In the BCLC staging system, sorafenib is recommended as a first-line option in advanced stage HCC[[2](#_ENREF_2),[3](#_ENREF_3)]. However, it was not available during the study period in Korea, and consequently, it could not be used as a treatment option in this study. Although sorafenib has been proven to improve survival in randomized controlled trials, its therapeutic advantages are modest[[38](#_ENREF_38),[39](#_ENREF_39)]. Thus, many clinical trials of combined loco-regional treatment and sorafenib have recently been conducted to improve patient outcome[[25](#_ENREF_25),[40](#_ENREF_40)].

In conclusion, TACE-based treatment in combination with other modalities was shown to be safe and more beneficial compared with conservative management in patients with large HCC and preserved hepatic function. Multimodal treatment was more effective than that of TACE only, and salvage surgery after successful downstaging achieved promising long-term results, suggesting that it is valuable in the treatment of patients with large, unresectable HCC. These results should be investigated further by prospective randomized controlled trials.

**comments**

***Background***

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer mortality. Although the Barcelona Clinic Liver Cancer (BCLC) staging system has been validated extensively, a heterogeneous population of patients with intermediate or advanced stage HCC has consistently raised issues in clinical practice. In addition, because multiple variables affect the clinical course of HCC, no single treatment strategy can be applied to all patients.

***Research frontiers***

Transarterial chemoembolization (TACE) is known to improve the survival of patients with unresectable HCC, compared to those who receive supportive treatment. Although TACE is typically contraindicated in advanced HCC patients with portal vein invasion (PV), it has been suggested that TACE can be safely performed even in those patients with PV invasion. Therefore, it has been used in patients with advanced HCC with PV invasion as a palliative treatment. However, only a limited number of studies have evaluated the proper treatment and the efficacy of TACE in cases of large HCCs (> 10 cm).

***Innovations and breakthroughs***

The authors revealed that overall survival and objective tumor response were significantly better in the TACE–based treatment group than in the conservative group. After subgroup analysis, survival benefits were observed not only in the multi-modal treatment group compared with the TACE-only group but also in the surgical treatment group compared with the loco-regional treatment-only group. Tumor stage and tumor type were two independent pre-treatment factors for survival. After adjusting for significant pre-treatment prognostic factors, objective response, surgical treatment, and multi-modal treatment were independent post-treatment prognostic factors.

***Applications***

In cases of advanced HCC, clinicians should attempt downstaging using aggressive treatment and a multimodal strategy and consider surgical treatment, such as resection or transplant, as an option if downstaging is successful.

***Terminology***

Multimodal treatment is a treatment strategy that combines various techniques, either as the first-line therapy or as a second-line approach after the failure of a monotherapy.

***Peer review***

The authors present an important, retrospective study on the outcome of TACE in 146 patients with large HCC, defined as >10 cm tumor diameter. Most patients underwent multimodal treatment, and a small subgroup could be downstaged to receive salvage surgery or transplantation.

**REFERENCES**

1 **Parkin DM**, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; **55**: 74-108 [PMID: 15761078]

2 **European Association For The Study Of The Liver**; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

3 **Bruix J**, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

4 **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; **359**: 1734-1739 [PMID: 12049862 DOI: 10.1016/s0140-6736(02)08649-x]

5 **Lo CM**, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; **35**: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]

6 **Llovet JM**, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003; **37**: 429-442 [PMID: 12540794 DOI: 10.1053/jhep.2003.50047]

7 **Cammà C**, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. *Radiology* 2002; **224**: 47-54 [PMID: 12091661]

8 **Lee HS**, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. *Cancer* 1997; **79**: 2087-2094 [PMID: 9179054]

9 **Kim KM**, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. *J Gastroenterol Hepatol* 2009; **24**: 806-814 [PMID: 19207681 DOI: 10.1111/j.1440-1746.2008.05728.x]

10 **Jang JW**, Bae SH, Choi JY, Oh HJ, Kim MS, Lee SY, Kim CW, Chang UI, Nam SW, Cha SB, Lee YJ, Chun HJ, Choi BG, Byun JY, Yoon SK. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. *Cancer Chemother Pharmacol* 2007; **59**: 9-15 [PMID: 16614848 DOI: 10.1007/s00280-006-0239-0]

11 **Yen FS**, Wu JC, Kuo BI, Chiang JH, Chen TZ, Lee SD. Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. *J Gastroenterol Hepatol* 1995; **10**: 237-240 [PMID: 7548796]

12 **Ueno S**, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, Hokotate H, Inoue H, Baba Y, Imamura Y, Aikou T. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. *Hepatol Res* 2002; **24**: 395-403 [PMID: 12479938]

13 **Lencioni R**, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 2010; **30**: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]

14 **Zhang BH**, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004; **130**: 417-422 [PMID: 15042359 DOI: 10.1007/s00432-004-0552-0]

15 **Yeh CN**, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. *Ann Surg Oncol* 2003; **10**: 1070-1076 [PMID: 14597446]

16 **Poon RT**, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. *J Am Coll Surg* 2002; **194**: 592-602 [PMID: 12022599]

17 **Choi GH**, Han DH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Park YN, Park JY, Kim do Y, Han KH, Chon CY, Lee WJ. Outcome after curative resection for a huge (& gt; or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. *Am J Surg* 2009; **198**: 693-701 [PMID: 19268907 DOI: 10.1016/j.amjsurg.2008.09.019]

18 **Becker G**, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. *World J Gastroenterol* 2005; **11**: 6104-6109 [PMID: 16273634]

19 **Cheng BQ**, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, Yi CH. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. *JAMA* 2008; **299**: 1669-1677 [PMID: 18398079 DOI: 10.1001/jama.299.14.1669]

20 **Koda M**, Murawaki Y, Mitsuda A, Oyama K, Okamoto K, Idobe Y, Suou T, Kawasaki H. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. *Cancer* 2001; **92**: 1516-1524 [PMID: 11745230]

21 **Shim SJ**, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. *Liver Int* 2005; **25**: 1189-1196 [PMID: 16343071 DOI: 10.1111/j.1478-3231.2005.01170.x]

22 **Guo WJ**, Yu EX, Liu LM, Li J, Chen Z, Lin JH, Meng ZQ, Feng Y. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. *World J Gastroenterol* 2003; **9**: 1697-1701 [PMID: 12918103]

23 **Kudo M**, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. *Eur J Cancer* 2011; **47**: 2117-2127 [PMID: 21664811 DOI: 10.1016/j.ejca.2011.05.007]

24 **Sansonno D**, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. *Oncologist* 2012; **17**: 359-366 [PMID: 22334456 DOI: 10.1634/theoncologist.2011-0313]

25 **Park JW**, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). *Liver Int* 2013; **33**: 327-337 [PMID: 23331661 DOI: 10.1111/liv.12083]

26 **Xia J**, Ren Z, Ye S, Sharma D, Lin Z, Gan Y, Chen Y, Ge N, Ma Z, Wu Z, Fan J, Qin L, Zhou X, Tang Z, Yang B. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. *Eur J Radiol* 2006; **59**: 407-412 [PMID: 16621394 DOI: 10.1016/j.ejrad.2006.03.002]

27 **Min YW**, Lee JH, Gwak GY, Paik YH, Lee JH, Rhee PL, Koh KC, Paik SW, Yoo BC, Choi MS. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching. *J Gastroenterol Hepatol* 2014; **29**: 1043-1048 [PMID: 24863186 DOI: 10.1111/jgh.12504]

28 **Fan J**, Tang ZY, Yu YQ, Wu ZQ, Ma ZC, Zhou XD, Zhou J, Qiu SJ, Lu JZ. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. *Dig Surg* 1998; **15**: 674-678 [PMID: 9845635]

29 **Tang ZY**, Zhou XD, Ma ZC, Wu ZQ, Fan J, Qin LX, Yu Y. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* 2004; **3**: 495-498 [PMID: 15567731]

30 **Lau WY**, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. *Ann Surg* 2004; **240**: 299-305 [PMID: 15273555]

31 **Yao FY**, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. *Hepatology* 2008; **48**: 819-827 [PMID: 18688876 DOI: 10.1002/hep.22412]

32 **Chapman WC**, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. *Ann Surg* 2008; **248**: 617-625 [PMID: 18936575 DOI: 10.1097/SLA.0b013e31818a07d4]

33 **Jang JW**, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, Kim DG, Choi JY. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. *Aliment Pharmacol Ther* 2010; **31**: 415-423 [PMID: 19821808 DOI: 10.1111/j.1365-2036.2009.04167.x]

34 **Song MJ**, Chun HJ, Song do S, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. *J Hepatol* 2012; **57**: 1244-1250 [PMID: 22824821 DOI: 10.1016/j.jhep.2012.07.017]

35 **Huang K**, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 920-925 [PMID: 24224722 DOI: 10.1111/jgh.12439]

36 **Salem R**, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 497-507.e2 [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049]

37 **Salem R**, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB, Mulcahy MF, Kulik L, Lewandowski R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. *Clin Gastroenterol Hepatol* 2013; **11**: 1358-1365.e1 [PMID: 23644386 DOI: 10.1016/j.cgh.2013.04.028]

38 **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/s1470-2045(08)70285-7]

39 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

40 **Kim HY**, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. *Liver Cancer* 2014; **3**: 9-17 [PMID: 24804173 DOI: 10.1159/000343854]

**P-Reviewer:** Braden b, Meshikhes AWN, Tai di **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Baseline characteristics of the patients *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **All (*n* = 146)** | **Treatment group (*n* = 119)** | **Conservative group (*n* = 27)** | ***P* value** |
| Age, yr | 52 (30-79) | 52 (30-77) | 58 (41-79) | 0.014 |
| Gender, male | 130 (89.0) | 111 (93.3) | 19 (70.4) | 0.002 |
| Etiologies, number |  |  |  | 0.385 |
| HBV/HCV/Alcohol/others | 115/7/8/16 | 95/4/7/13 | 20/3/1/3 |  |
| AFP, ng/mL | 546.7  (0.7-5719.0) | 471.2  (0.7-5719.0) | 1210.0  (3.1-2613.0) | 0.652 |
| Maximal tumor size, cm | 12.0  (10.0-20.0) | 12.0  (10.0-20.0) | 11.2  (10.0-17.0) | 0.459 |
| Tumor type |  |  |  | 0.551 |
| Well-demarcated | 99 (67.8) | 82 (68.9) | 17 (63.0) |  |
| Poorly-demarcated | 47 (32.2) | 37 (31.1) | 10 (37.0) |  |
| Location of main tumor |  |  |  | 0.369 |
| Left | 24 (16.4) | 18 (15.1) | 6 (22.2) |  |
| Right | 122 (83.6) | 101 (84.9) | 21 (77.8) |  |
| PVT |  |  |  | 0.637 |
| Present | 108 (74.0) | 89 (74.8) | 19 (70.4) |  |
| Absent | 38 (26.0) | 30 (25.2) | 8 (29.6) |  |
| Stage, modified UICC |  |  |  | 0.491 |
| Stage III | 67 (45.9) | 53 (44.5) | 14 (51.9) |  |
| Stage IV-A | 79 (54.1) | 66 (55.5) | 13 (48.1) |  |

HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: alpha-fetoprotein; PVT: portal vein thrombosis; UICC: Union for International Cancer Control.

**Table 2 Objective response and disease control rate *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Objective response** | **Non-response** | **Disease control** | **Progressive disease** |
| Treatment group (*n* = 102) | 29 (28.4) | 73 (71.6) | 60 (58.8) | 42 (41.2) |
| Conservative group (*n* = 20) | 0 (0) | 20 (100) | 3 (15) | 17 (85) |
| *P* value | 0.003 | | < 0.001 | |

Evaluation of tumor response was not possible in 17 (14.3% within treatment group) and 7 (25.9%, within conservative group) out of 146 patients.

**Table 3 Estimated 6-, 12-, 18-, and 24-mo survival rate**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | 6 mo | 12 mo | 18 mo | 24 mo |
| Treatment group, total (*n* = 119) | 72.0% | 43.0% | 28.2% | 23.5% |
| Surgical treatment (*n* = 17) | 88.2% | 76.5% | 64.7% | 64.7% |
| Localized treatment (*n* = 102) | 69.3% | 37.3% | 22.0% | 16.4% |
| Conservative group (*n* = 27) | 18.5% | 3.7% | 0% | 0% |
| *P*-value | < 0.001 | < 0.001 | < 0.001 | < 0.001 |

**Table 4 Pre-treatment prognostic factors for survival in the treatment group**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Factors** | **Univariate analysis** | | | **Multivariate analysis** | | |
| **HR** | **95%CI** | ***P* value** | **HR** | **95%CI** | ***P* value** |
| Age  (< 60 *vs* ≥ 60 yr) | 0.634 | 0.393-1.023 | 0.062 |  |  |  |
| Gender  (female *vs* male) | 0.768 | 0.373-1.584 | 0.475 |  |  |  |
| CTP score  (5 *vs* 6) | 1.292 | 0.839-1.990 | 0.245 |  |  |  |
| AFP  (< 1000 *vs* ≥ 1000 ng/mL) | 1.346 | 0.914-1.982 | 0.132 |  |  |  |
| Maximal tumor size  (< 15 *vs* ≥ 15 cm) | 1.342 | 0.842-2.140 | 0.216 |  |  |  |
|
| Tumor type  (well-demarcated vs. poorly-demarcated) | 2.689 | 1.721-4.203 | < 0.001 | 1.849 | 1.165-2.934 | 0.009 |
|
|
| Portal vein thrombosis (absent *vs* present) | 2.43 | 1.519-3.888 | < 0.001 |  |  |  |
|
| Stage (III *vs* IV-A) | 3.344 | 2.108-5.304 | < 0.001 | 2.828 | 1.740-4.595 | < 0.001 |

AFP: alpha-fetoprotein.

**Table 5 Treatment-related prognostic factors in the treatment group**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Factors** | **Univariate analysis** | | | **Multivariate analysis** | | |
| **HR** | **95%CI** | ***P* value** | **HR1** | **95%CI** | ***P* value2** |
| Objective response  (Present *vs* absent) | 3.591 | 2.129-6.056 | < 0.001 | 2.87 | 1.678-4.910 | < 0.001 |
| Surgical treatment  (Yes *vs* No) | 2.9 | 1.634-5.147 | < 0.001 | 2.301 | 1.227-4.317 | 0.009 |
| Multimodality  (Yes *vs* No) | 1.743 | 1.198-2.536 | 0.004 | 1.835 | 1.242-2.714 | 0.002 |

1Adjusted HR for tumor type and stage; 2*P* for adjusted hazard ratio.

Table 6 Comparison of baseline characteristics between the surgical treatment group and the non-surgical treatment group *n* (%)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **All (*n =* 119)** | **Surgical treatment group (*n =* 17)** | **Non-surgical treatment group (*n =* 102)** | ***P* value** |
| Age, yr | 52 (30-77) | 52 (30-74) | 51.5 (32-77) | 0.814 |
| Gender, male | 111 (93.3) | 15 (88.2) | 96 (94.1) | 0.32 |
| Etiologies, number |  |  |  | 0.704 |
| HBV/HCV/Alcohol/others | 95/4/7/13 | 12/1/1/3 | 83/3/6/10 |  |
| AFP, ng/mL | 471.2 | 261.8 | 603.6 | 0.879 |
| (0.7-5719.0) | (0.7-5719.0) | (1.9-5102.0) |
| Maximal tumor size, cm | 12 | 12 | 12 | 0.904 |
| (10.0-20.0) | (10.0-16.0) | (10.0-20.0) |
| Tumor type |  |  |  | 0.051 |
| Well-demarcated | 82 (68.9) | 15 (88.2) | 67 (65.7) |  |
| Poorly-demarcated | 37 (31.1) | 2 (11.8) | 35 (34.3) |  |
| Location of main tumor |  |  |  | 0.085 |
| Left | 18 (15.1) | 5 (29.4) | 13 (12.7) |  |
| Right | 101 (84.9) | 12 (70.6) | 89 (87.3) |  |
| PVT |  |  |  | 0.094 |
| Present | 89 (74.8) | 10 (58.8) | 79 (77.5) |  |
| Absent | 30 (25.2) | 7 (41.2) | 23 (22.5) |  |
| Stage, modified UICC |  |  |  | 0.071 |
| Stage III | 53 (44.5) | 11 (64.7) | 42 (41.2) |  |
| Stage IV-A | 66 (55.5) | 6 (35.3) | 60 (58.8) |  |

HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: alpha-fetoprotein; PVT: portal vein thrombosis; UICC: Union for International Cancer Control.



**Figure 1 Treatment protocol.** TACE: transarterial chemoembolization; RFA: radiofrequency ablation; PEI: percutaneous ethanol injection.



**Figure 2 Overall survival according to the Kaplan-Meier method.** Significantly better overall survival rates were observed (A) in the treatment group compared with the conservative group (*P <* 0.001), (B) in the surgical treatment group compared with the loco-regional treatment group (*P <* 0.001), and (C) in the multi-modal treatment group compared with the single modality group (*P* = 0.002).



**Figure 3 Representative example of multi-modal treatment.** A: A 46-year-old male patient had a large hepatocellular carcinoma measuring 11 cm in diameter in the right hepatic lobe; B: TACE was performed; C: After 6 sessions of TACE, 7 sessions of PEI, 6 cycles of systemic chemotherapy, and external radiation therapy, the tumor mass was remarkably reduced; D: After right hepatectomy, 2 cycles of adjuvant chemotherapy were administered. However, two metastatic nodules occurred, one in each lung without hepatic recurrence at 5 mo after right hepatectomy; E: Wedge resection for metastatic lung nodules was performed, and no hepatic and pulmonary recurrences were observed until 12 years after hepatectomy and metastasectomy. TACE: transarterial chemoembolization; PEI: percutaneous ethanol injection.